WO2001038349A2 - NEUE ss-DEFENSINE - Google Patents
NEUE ss-DEFENSINE Download PDFInfo
- Publication number
- WO2001038349A2 WO2001038349A2 PCT/EP2000/011770 EP0011770W WO0138349A2 WO 2001038349 A2 WO2001038349 A2 WO 2001038349A2 EP 0011770 W EP0011770 W EP 0011770W WO 0138349 A2 WO0138349 A2 WO 0138349A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- defensins
- defensin according
- defensin
- carboxyl group
- infections
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to new ß-defensins according to claim 1, medicaments containing the ß-defensins according to the invention and uses of the ß-defensins according to the invention.
- Defensins are polypeptides with an antibiotic effect. Due to the increasing resistance to antibiotics, particularly of pathogenic microorganisms, it is imperative to supplement the arsenal of antibiotic substances in order to successfully combat these microorganisms. Defensins are expressed in various tissues and organs in mammals.
- the technical problem on which the invention was based was to provide further effective defensins which can be used, inter alia, as medicaments.
- Z 1 and Z 2 are the same or different
- Z 1 denotes a substituted or unsubstituted amino acid residue with at least one further Cys
- Z 2 means either a peptide residue of up to 20 amino acids with at least two immediately adjacent Cys or a carboxyl group or a derivatized carboxyl group.
- Z 1 is QDINSKRACYREGGECLQ and / or QKINEPVSCIRNGGICQY and Z 2 is NFRFKCCKFQIPEKKTKIL and / or GSPFKCCK.
- Fig. La shows some amino acid sequences of human and murine ⁇ -defensins.
- the ⁇ -defensins which are particularly preferred according to the invention are mBD5 (Seq ID. No 1) and mBD6 (Seq ID. No 2).
- the other sequences mBD1 to mBD4 originate from the mouse and are known per se, as are the sequences hBD1 and hBD2. The latter come from humans.
- Fig. Lb shows the ⁇ -defensins mBD5 (Seq ID. No 1) and mBD6 (Seq ID. No 2) according to the invention.
- FIG. 2 shows an expression pattern of the ⁇ -defensin mBD5 according to the invention in various tissues or organs of the mouse.
- the ordinate is given in relative expression units.
- FIG. 3 shows an expression pattern of the ⁇ -defensin mBD6 according to the invention in various tissues or organs of the mouse.
- the ordinate is given in relative expression units.
- FIG. 4 shows in table form the minimum inhibitory concentration (MIC minimum inhibitory concentration) of the ⁇ -defensins according to the invention against various microorganisms. The values are given in ⁇ g / mL.
- 5 shows a dose-response curve of the ⁇ -defensins according to the invention. The ordinate of the upper curve shows the cfu value (colony forming units), the abscissa the increasing concentration of the ß-defensin mBD5 and the derived determination of the IC 50 value (inhibitory concentration) for mBD5 against E. coli. The lower curve shows this accordingly for mBD6.
- FIG. 6 shows the regulation of the ⁇ -defensin mBD5 according to the invention in NIH-3T3 cells.
- the ordinate shows relative expression units.
- the medicaments according to the invention contain at least one ⁇ -defensin according to the invention as an active ingredient.
- the skilled worker is familiar with the auxiliaries and excipients which can optionally be used as pharmaceuticals for the formulation of the ⁇ -defensins.
- the ß-defensins can be used in amounts that are defined by their therapeutic range. They are typically used in amounts of 1 ⁇ g to 100 mg.
- formulations of the ⁇ -defensins according to the invention as a solution for intravenous, intramuscular, subcutaneous and topical application are preferred.
- the ⁇ -defensins according to the invention are suitable for the treatment of infections.
- the ⁇ -defensins according to the invention can be used as antibiotically active substances.
- the antibiotic spectrum of the ⁇ -defensins according to the invention is wide and is sufficient, for example, to treat infections caused by multidrug-resistant pathogens, such as streptococcus, bacillus, Pseudomonas, Echerichia, staphylococcus and candida.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU23593/01A AU2359301A (en) | 1999-11-26 | 2000-11-25 | Novel ss-defensins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19957043.4 | 1999-11-26 | ||
DE1999157043 DE19957043A1 (de) | 1999-11-26 | 1999-11-26 | Neue Defensine |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001038349A2 true WO2001038349A2 (de) | 2001-05-31 |
WO2001038349A3 WO2001038349A3 (de) | 2002-05-10 |
Family
ID=7930487
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2000/011770 WO2001038349A2 (de) | 1999-11-26 | 2000-11-25 | NEUE ss-DEFENSINE |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2359301A (de) |
DE (1) | DE19957043A1 (de) |
WO (1) | WO2001038349A2 (de) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024992A2 (en) * | 2001-09-21 | 2003-03-27 | University Of Iowa Research Foundation | HUMAN AND MOUSE β-DEFENSINS, ANTIMICROBIAL PEPTIDES |
WO2004054603A2 (en) * | 2002-12-13 | 2004-07-01 | Case Western Reserve University | Use of beta-defensins for treating hiv infections |
WO2004055041A2 (en) * | 2002-12-13 | 2004-07-01 | Case Western Reserve University | Defensin-inducing peptides from fusobacterium |
WO2006103037A2 (de) * | 2005-03-29 | 2006-10-05 | Henkel Kommanditgesellschaft Auf Aktien | ZUSAMMENSETZUNG ENTHALTEND β-DEFENSIN 2 |
US7442375B2 (en) | 2002-12-13 | 2008-10-28 | Case Western Reserve University | Compositions of beta-defensin inducing agents |
US20110251139A1 (en) * | 2008-07-18 | 2011-10-13 | Novozymes A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
US9217021B2 (en) | 2011-07-08 | 2015-12-22 | Defensin Therapeutics Aps | Oral treatment of inflammatory bowel disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999013080A1 (en) * | 1997-09-10 | 1999-03-18 | Zymogenetics, Inc. | Beta-defensins |
-
1999
- 1999-11-26 DE DE1999157043 patent/DE19957043A1/de not_active Withdrawn
-
2000
- 2000-11-25 AU AU23593/01A patent/AU2359301A/en not_active Abandoned
- 2000-11-25 WO PCT/EP2000/011770 patent/WO2001038349A2/de active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999013080A1 (en) * | 1997-09-10 | 1999-03-18 | Zymogenetics, Inc. | Beta-defensins |
Non-Patent Citations (1)
Title |
---|
LIU L ET AL: "Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation" GENE,NL,ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, Bd. 222, Nr. 2, November 1998 (1998-11), Seiten 237-244, XP004150052 ISSN: 0378-1119 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024992A2 (en) * | 2001-09-21 | 2003-03-27 | University Of Iowa Research Foundation | HUMAN AND MOUSE β-DEFENSINS, ANTIMICROBIAL PEPTIDES |
WO2003024992A3 (en) * | 2001-09-21 | 2003-07-10 | Univ Iowa Res Found | HUMAN AND MOUSE β-DEFENSINS, ANTIMICROBIAL PEPTIDES |
US7655242B2 (en) | 2002-12-13 | 2010-02-02 | Case Western Reserve University | Defensin-inducing agents |
WO2004055041A2 (en) * | 2002-12-13 | 2004-07-01 | Case Western Reserve University | Defensin-inducing peptides from fusobacterium |
WO2004055041A3 (en) * | 2002-12-13 | 2004-10-28 | Univ Case Western Reserve | Defensin-inducing peptides from fusobacterium |
WO2004054603A3 (en) * | 2002-12-13 | 2004-11-18 | Univ Case Western Reserve | Use of beta-defensins for treating hiv infections |
US7442375B2 (en) | 2002-12-13 | 2008-10-28 | Case Western Reserve University | Compositions of beta-defensin inducing agents |
WO2004054603A2 (en) * | 2002-12-13 | 2004-07-01 | Case Western Reserve University | Use of beta-defensins for treating hiv infections |
WO2006103037A2 (de) * | 2005-03-29 | 2006-10-05 | Henkel Kommanditgesellschaft Auf Aktien | ZUSAMMENSETZUNG ENTHALTEND β-DEFENSIN 2 |
WO2006103037A3 (de) * | 2005-03-29 | 2007-03-22 | Henkel Kgaa | ZUSAMMENSETZUNG ENTHALTEND β-DEFENSIN 2 |
US20110251139A1 (en) * | 2008-07-18 | 2011-10-13 | Novozymes A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
US8802621B2 (en) * | 2008-07-18 | 2014-08-12 | Defensin Therapeutics Aps | Treatment of inflammatory bowel diseases with mammal beta defensins |
US9279010B2 (en) | 2008-07-18 | 2016-03-08 | Defensin Therapeutics Aps | Treatment of inflammatory bowel diseases with mammal beta defensins |
US9217021B2 (en) | 2011-07-08 | 2015-12-22 | Defensin Therapeutics Aps | Oral treatment of inflammatory bowel disease |
US9833495B2 (en) | 2011-07-08 | 2017-12-05 | Defensin Therapeutics Aps | Oral treatment of inflammatory bowel disease |
Also Published As
Publication number | Publication date |
---|---|
WO2001038349A3 (de) | 2002-05-10 |
AU2359301A (en) | 2001-06-04 |
DE19957043A1 (de) | 2001-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69734661T2 (de) | Foerderung der wundheilung durch chemisch modifizierte tetracycline | |
DE69833131T2 (de) | Metal/thiol enthaltende biozidemittel | |
DE69025927T2 (de) | Zusammensetzung und behandlung mit biologisch aktiven peptiden und antibiotika | |
EP1658040B1 (de) | Produkt mit silber und zink | |
EP0203580B1 (de) | Gamma-IFN als Wirkstoff zur Hemmung (Verhinderung) von Abbauprozessen im Knochen | |
DE69920877T2 (de) | Antimikrobiell wirksame peptide | |
WO1999032620A9 (de) | Insulin-like growth factor binding protein fragmente und ihre verwendung | |
WO2013132005A1 (de) | Antimikrobielle peptide | |
WO2001038349A2 (de) | NEUE ss-DEFENSINE | |
DE68919848T2 (de) | Amphiphile peptide und deren verwendung. | |
EP0438756B1 (de) | Cytostatische und cytotoxische Wirkstoffkombination zur Anwendung in therapeutischen Verfahren | |
DE112011100556T5 (de) | Gering hämolytisches antimimikrobielles Peptid, dessen pharmazeutische Zusammensetzung und Verwendung | |
WO2002100895A2 (de) | Antimikrobiell wirkendes peptid | |
WO2000046245A2 (de) | Humane antibiotische proteine | |
DE69002881T2 (de) | Peptide und deren Benutzung. | |
DE69101755T2 (de) | Verwendung von Phosphomycin pharmazeutisch akzeptierbare Salze als topisches Wundheilungsmittel. | |
DE68918453T2 (de) | Zusammensetzungen auf Basis von CPF Peptiden sowie deren Verwendungen. | |
DE202022102100U1 (de) | Synergistische antibiotische pharmazeutische Zusammensetzung zur Behandlung von Staphylococcus aureus-Infektionen | |
WO2008009655A2 (de) | Medizinische verwendung von n-phenylpropenoyl-aminosäurederivaten und verwandten verbindungen | |
DE10004667A1 (de) | Neues ß-Defensin, hBD-3, Herstellung und seine Anwendung | |
EP1214345A2 (de) | Mittel zur therapie von menschlichen erkrankungen, insbesondere für die therapie von tumoren wie kolonkarzinomen und melanomen oder zur geweberegeneration und förderung des haarwuchses | |
EP4001293A1 (de) | Tetrapeptid und dessen verwendung | |
EP3682913B1 (de) | Bakterienresistente und -abweisende, biokompatible oberfläche für in hart- und weichgewebe integrierte implantate, schrauben und platten | |
AT505156A4 (de) | Ein neues defensin | |
DE2934402A1 (de) | Zur appetitregelung durch wirkung spezifisch auf das ernaehrungszentrum geeigneter wirkstoff, verfahren zu dessen herstellung und diesen enthaltende arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |